CytomX Therapeutics Inc (NASDAQ:CTMX) CEO Sean A. Mccarthy sold 2,028 shares of the company’s stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $25.09, for a total transaction of $50,882.52. Following the completion of the sale, the chief executive officer now owns 84,091 shares of the company’s stock, valued at approximately $2,109,843.19. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Sean A. Mccarthy also recently made the following trade(s):
Get CytomX Therapeutics alerts: On Monday, July 2nd, Sean A. Mccarthy sold 13,052 shares of CytomX Therapeutics stock. The shares were sold at an average price of $23.42, for a total transaction of $305,677.84.CytomX Therapeutics traded up $0.17, reaching $25.15, during trading hours on Friday, Marketbeat.com reports. 323,500 shares of the stock were exchanged, compared to its average volume of 390,321. The stock has a market cap of $972.77 million, a PE ratio of -21.53 and a beta of 0.92. CytomX Therapeutics Inc has a 12 month low of $13.09 and a 12 month high of $35.00.
CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Wednesday, May 9th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.17). The firm had revenue of $14.18 million for the quarter, compared to the consensus estimate of $19.77 million. CytomX Therapeutics had a negative return on equity of 92.68% and a negative net margin of 67.88%. equities analysts expect that CytomX Therapeutics Inc will post -1.59 earnings per share for the current year.
CTMX has been the subject of a number of recent analyst reports. Jefferies Financial Group upped their price objective on shares of CytomX Therapeutics to $40.00 and gave the company a “buy” rating in a research report on Thursday, March 8th. Bank of America upped their price objective on shares of CytomX Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, March 8th. Cantor Fitzgerald set a $40.00 price objective on shares of CytomX Therapeutics and gave the company a “buy” rating in a research report on Thursday, March 8th. BidaskClub cut shares of CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 30th. Finally, Cowen restated a “buy” rating on shares of CytomX Therapeutics in a research report on Thursday, May 10th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. CytomX Therapeutics currently has an average rating of “Buy” and an average price target of $38.38.
A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in CytomX Therapeutics by 28.5% during the 4th quarter. BlackRock Inc. now owns 2,646,599 shares of the biotechnology company’s stock worth $55,870,000 after purchasing an additional 586,698 shares in the last quarter. Perceptive Advisors LLC increased its holdings in CytomX Therapeutics by 79.1% during the 4th quarter. Perceptive Advisors LLC now owns 2,490,381 shares of the biotechnology company’s stock worth $52,571,000 after purchasing an additional 1,100,000 shares in the last quarter. Millennium Management LLC increased its holdings in CytomX Therapeutics by 34.0% during the 4th quarter. Millennium Management LLC now owns 837,415 shares of the biotechnology company’s stock worth $17,678,000 after purchasing an additional 212,423 shares in the last quarter. Renaissance Technologies LLC increased its holdings in CytomX Therapeutics by 32.9% during the 4th quarter. Renaissance Technologies LLC now owns 715,100 shares of the biotechnology company’s stock worth $15,096,000 after purchasing an additional 177,200 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in CytomX Therapeutics by 40.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 457,619 shares of the biotechnology company’s stock worth $9,660,000 after purchasing an additional 132,454 shares in the last quarter. Hedge funds and other institutional investors own 76.24% of the company’s stock.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
No comments:
Post a Comment